Section Arrow
ZYME.NASDAQ
- Zymeworks
Quotes are at least 15-min delayed:2026/03/09 16:34 EDT
After Hours
Last
 23.9
-0.37 (-1.52%)
Bid
23.88
Ask
26
High 24.5 
Low 23.9 
Volume 13.34K 
Regular Hours (Closed)
Last
 24.27
+0.19 (+0.79%)
Day High 
24.91 
Prev. Close
24.08 
1-M High
25.755 
Volume 
57 
Bid
23.88
Ask
26
Day Low
23.875 
Open
23.875 
1-M Low
22.07 
Market Cap 
1.82B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.97 
20-SMA 23.41 
50-SMA 23.88 
52-W High 28.49 
52-W Low 9.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.85/-1.52
Enterprise Value
1.83B
Balance Sheet
Book Value Per Share
4.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
76.30M
Operating Revenue Per Share
6.12
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ANTXAN2 Therapeutics5.25+2.41+84.86%-- 
After Hours 5.1 -0.15 -2.86%
RLMDRelmada Therapeutics7.17+2.72+61.12%-- 
After Hours 6.77 -0.4 -5.58%
IOVAIovance Biotherapeutics5.41+0.275+5.36%-- 
After Hours 5.3635 -0.0465 -0.86%
IBRXImmunityBio8.45-0.2-2.31%-- 
After Hours 8.46 +0.01 +0.12%
QNCXQuince Therapeutics0.1065+0.0042+4.11%-- 
After Hours 0.1051 -0.0014 -1.31%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.